University of Guayaquil School

Faculty Natural Sciences

School of Biology
Topic:
Natural Products and Biological Activity of the
Pharmacologically Active
Cauliflower Mushroom Sparassis crispa
Members:
Abad Jorge
Bastidas Joel
Cabrera Daniela
Taxonomy
Kingdom: Fungi
Phylum: Basidiomycota
Class: Agaricomycetes
Order: Polyporales
Family: Sparassidaceae
Genre: Sparassis
Species: Sparassis crispa
Description
• Carpoforo can reach
remarkable dimensions,
some specimens can reach
40 cm long by 20 or 25
high.
• Smooth white or creamy
himenio, darkens gradually,
especially as a result of
ripening.
• Very short whitish foot with
cauliflower stem
appearance from which the
ramifications
Thin and fragile flesh, yellowish
white, its smell is aromatic and
very patent, slightly aniseed in
the harvest and later complex
sweet, its flavor is like nuts.

It is a fungus of brown rot that

grows mainly on the trunks of
coniferous trees and is widely
distributed in the temperate zone
of the northern hemisphere.
During the last 2 to 3 decades,
scientific and medical research
in Japan, China, Korea and
more recently in the United
States, has shown increasingly
powerful and unique
properties of compounds
extracted from mushrooms for
the prevention and treatment
of cancer and other chronic
diseases.
 Antidiabetic
Activity
Antitumor and
Antihypertensive Anticarcinogenic
Effects Activity (except
for SCG)

Pharmacological
Antiviral Antiallergic
Aspects of S.
Activity crispa Activity
 HUMAN CLINICAL EVALUATION
• Healthy men were given S. crispa powder orally at 300mg per
day for 8 weeks.
• NK cell cytotoxicity was significantly enhanced without increasing the
number of NK cells.
• Kimura investigated whether dietary S. crispa influenced human skin
condition.
• Did another test oral administration of S. crispa powder
(320mg/day) for 28 consecutive days.
• Where the transepidermal water loss was drastically reduced, giving as
an indicator the barrier function of the skin.
 HUMAN CLINICAL EVALUATION
• The placebo group continued with the same dose during the trial
period.
• The oral administration of S. crispa has a positive effect on the skin
barrier.
• This trial was used in patients with different types of cancer who have
performed a single lymphocyte transfer immunotherapy.
• Patients 14 cases in a follow-up period of 15 months
resulted in an improvement in quality of life in 9 cases.